RU2018104702A - Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ - Google Patents
Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ Download PDFInfo
- Publication number
- RU2018104702A RU2018104702A RU2018104702A RU2018104702A RU2018104702A RU 2018104702 A RU2018104702 A RU 2018104702A RU 2018104702 A RU2018104702 A RU 2018104702A RU 2018104702 A RU2018104702 A RU 2018104702A RU 2018104702 A RU2018104702 A RU 2018104702A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- alkyl
- hydrogen
- amino
- pyrrolo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 35
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 58
- 229910052739 hydrogen Inorganic materials 0.000 claims 48
- 239000001257 hydrogen Substances 0.000 claims 48
- 229910052736 halogen Inorganic materials 0.000 claims 27
- 150000002367 halogens Chemical class 0.000 claims 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 24
- 150000002431 hydrogen Chemical class 0.000 claims 22
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- -1 hydroxy, methoxy Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000035755 proliferation Effects 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 4
- 206010013774 Dry eye Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- UOFYSRZSLXWIQB-UHFFFAOYSA-N abivertinib Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 UOFYSRZSLXWIQB-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 150000003840 hydrochlorides Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- IQVPLUKZZPRFMX-UHFFFAOYSA-N C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=C(N=1)NC1=CC=C(C=C1)N1CCN(CC1)C)NCC2(N1CCCC1)CCO Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)OC=1C2=C(N=C(N=1)NC1=CC=C(C=C1)N1CCN(CC1)C)NCC2(N1CCCC1)CCO IQVPLUKZZPRFMX-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 1
- UTDDJJUGDRITRM-UHFFFAOYSA-N n-[3-[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7-(hydroxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2CO)C2=N1 UTDDJJUGDRITRM-UHFFFAOYSA-N 0.000 claims 1
- DCGRPOGHWQLKOZ-UHFFFAOYSA-N n-[3-[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7-methylsulfonylpyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2S(C)(=O)=O)C2=N1 DCGRPOGHWQLKOZ-UHFFFAOYSA-N 0.000 claims 1
- CRQWCDVENQWZCN-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]-7-methylsulfonylpyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2S(C)(=O)=O)C2=N1 CRQWCDVENQWZCN-UHFFFAOYSA-N 0.000 claims 1
- HFYLURUSCWSASY-UHFFFAOYSA-N n-[3-[7-(2-fluoroethyl)-2-[4-(4-methylpiperazin-1-yl)anilino]pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2CCF)C2=N1 HFYLURUSCWSASY-UHFFFAOYSA-N 0.000 claims 1
- ONANSSHSCHBJKW-UHFFFAOYSA-N n-[3-[7-(hydroxymethyl)-2-[4-(4-methylpiperazin-1-yl)anilino]pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2CO)C2=N1 ONANSSHSCHBJKW-UHFFFAOYSA-N 0.000 claims 1
- LZBGRUIJNCMSRE-UHFFFAOYSA-N n-[3-[7-(hydroxymethyl)-2-[[6-(4-methylpiperazin-1-yl)pyridin-3-yl]amino]pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2CO)C2=N1 LZBGRUIJNCMSRE-UHFFFAOYSA-N 0.000 claims 1
- SKHUJQVFPTVJKH-UHFFFAOYSA-N n-[3-[7-acetyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2C(C)=O)C2=N1 SKHUJQVFPTVJKH-UHFFFAOYSA-N 0.000 claims 1
- NZZVCUOQSPFXRA-UHFFFAOYSA-N n-[3-[7-cyclopropyl-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2C3CC3)C2=N1 NZZVCUOQSPFXRA-UHFFFAOYSA-N 0.000 claims 1
- UAZRAOVSYBDSMH-UHFFFAOYSA-N n-[3-[7-cyclopropyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrrolo[2,3-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2C3CC3)C2=N1 UAZRAOVSYBDSMH-UHFFFAOYSA-N 0.000 claims 1
- UAXPROIZGYSMOO-UHFFFAOYSA-N n-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-5-(2-hydroxyethyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(CCO)=CN2)C2=N1 UAXPROIZGYSMOO-UHFFFAOYSA-N 0.000 claims 1
- OSKRLMPMNNECGD-UHFFFAOYSA-N n-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-5-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)N3CCCCC3)C2=N1 OSKRLMPMNNECGD-UHFFFAOYSA-N 0.000 claims 1
- HXOJLOVOBMQWOX-UHFFFAOYSA-N n-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-5-pyrrolidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)N3CCCC3)C2=N1 HXOJLOVOBMQWOX-UHFFFAOYSA-N 0.000 claims 1
- SETKZRJYZNZHMO-UHFFFAOYSA-N n-[3-[[2-[4-(4-methylpiperazin-1-yl)anilino]-5-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)N3CCCCC3)C2=N1 SETKZRJYZNZHMO-UHFFFAOYSA-N 0.000 claims 1
- KARQYIZIHFFBDR-UHFFFAOYSA-N n-[3-[[2-[4-(4-methylpiperazin-1-yl)anilino]-5-pyrrolidin-1-yl-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)N3CCCC3)C2=N1 KARQYIZIHFFBDR-UHFFFAOYSA-N 0.000 claims 1
- HAJRCWPFNCVVCY-UHFFFAOYSA-N n-[3-[[2-[4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 HAJRCWPFNCVVCY-UHFFFAOYSA-N 0.000 claims 1
- YFIMTIUAPOZBKY-UHFFFAOYSA-N n-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C=1C=C(NC=2N=C3NC=CC3=C(NC=3C=C(NC(=O)C=C)C=CC=3)N=2)C(OC)=CC=1NC1CN(CCF)C1 YFIMTIUAPOZBKY-UHFFFAOYSA-N 0.000 claims 1
- QXIPKEVCAWHBBL-UHFFFAOYSA-N n-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C=1C=C(NC=2N=C3NC=CC3=C(OC=3C=C(NC(=O)C=C)C=CC=3)N=2)C(OC)=CC=1NC1CN(CCF)C1 QXIPKEVCAWHBBL-UHFFFAOYSA-N 0.000 claims 1
- WGBLPNFSWJRFER-UHFFFAOYSA-N n-[3-[[2-[[1-[2-(dimethylamino)ethyl]indol-5-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C=1C=C2N(CCN(C)C)C=CC2=CC=1NC(N=C1NC=CC1=1)=NC=1OC1=CC=CC(NC(=O)C=C)=C1 WGBLPNFSWJRFER-UHFFFAOYSA-N 0.000 claims 1
- MMYFQTGWGGGYML-UHFFFAOYSA-N n-[3-[[2-[[2-(piperidin-1-ylmethyl)quinolin-6-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C=CC(=O)NC1=CC=CC(OC=2C=3C=CNC=3N=C(NC=3C=C4C=CC(CN5CCCCC5)=NC4=CC=3)N=2)=C1 MMYFQTGWGGGYML-UHFFFAOYSA-N 0.000 claims 1
- REVVHHDVZSEMTI-UHFFFAOYSA-N n-[3-[[2-[[2-[(dimethylamino)methyl]quinolin-6-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1=CC2=NC(CN(C)C)=CC=C2C=C1NC(N=C1NC=CC1=1)=NC=1OC1=CC=CC(NC(=O)C=C)=C1 REVVHHDVZSEMTI-UHFFFAOYSA-N 0.000 claims 1
- PEOCEMXAFXTVAE-UHFFFAOYSA-N n-[3-[[2-[[6-(4-methylpiperazin-1-yl)pyridin-3-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 PEOCEMXAFXTVAE-UHFFFAOYSA-N 0.000 claims 1
- PPIDHDMRNYAPQN-UHFFFAOYSA-N n-[3-[[5-(azetidin-1-yl)-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)N3CCC3)C2=N1 PPIDHDMRNYAPQN-UHFFFAOYSA-N 0.000 claims 1
- HSSHUAJCPXEROO-UHFFFAOYSA-N n-[3-[[5-(azetidin-1-yl)-2-[4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)N3CCC3)C2=N1 HSSHUAJCPXEROO-UHFFFAOYSA-N 0.000 claims 1
- DERXCLHUGPTWMG-UHFFFAOYSA-N n-[3-[[5-(aziridin-1-yl)-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)N3CC3)C2=N1 DERXCLHUGPTWMG-UHFFFAOYSA-N 0.000 claims 1
- ZJXKBKHHAXBPTH-UHFFFAOYSA-N n-[3-[[5-(dimethylamino)-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N=1C(OC=2C=C(NC(=O)C=C)C=CC=2)=C2C(N(C)C)=CNC2=NC=1NC(C=C1F)=CC=C1N1CCN(C)CC1 ZJXKBKHHAXBPTH-UHFFFAOYSA-N 0.000 claims 1
- SIGRAWNPFKTSBV-UHFFFAOYSA-N n-[3-[[5-(dimethylamino)-2-[4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N=1C(OC=2C=C(NC(=O)C=C)C=CC=2)=C2C(N(C)C)=CNC2=NC=1NC(C=C1)=CC=C1N1CCN(C)CC1 SIGRAWNPFKTSBV-UHFFFAOYSA-N 0.000 claims 1
- MKBDTRHCEROTFU-UHFFFAOYSA-N n-[3-[[5-[(dimethylamino)methyl]-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N=1C(OC=2C=C(NC(=O)C=C)C=CC=2)=C2C(CN(C)C)=CNC2=NC=1NC(C=C1F)=CC=C1N1CCN(C)CC1 MKBDTRHCEROTFU-UHFFFAOYSA-N 0.000 claims 1
- PHNGGJAITPBPLC-UHFFFAOYSA-N n-[3-[[5-[2-(dimethylamino)ethyl]-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N=1C(OC=2C=C(NC(=O)C=C)C=CC=2)=C2C(CCN(C)C)=CNC2=NC=1NC(C=C1F)=CC=C1N1CCN(C)CC1 PHNGGJAITPBPLC-UHFFFAOYSA-N 0.000 claims 1
- LWJSAYXNTLJFNR-UHFFFAOYSA-N n-[3-[[5-[2-(dimethylamino)ethyl]-2-[4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound N=1C(OC=2C=C(NC(=O)C=C)C=CC=2)=C2C(CCN(C)C)=CNC2=NC=1NC(C=C1)=CC=C1N1CCN(C)CC1 LWJSAYXNTLJFNR-UHFFFAOYSA-N 0.000 claims 1
- BCIZOTIPJMSBAY-UHFFFAOYSA-N n-[3-[[5-cyclopropyl-2-[4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C(=CN2)C3CC3)C2=N1 BCIZOTIPJMSBAY-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680231P | 2012-08-06 | 2012-08-06 | |
| US61/680,231 | 2012-08-06 | ||
| US13/843,554 US9034885B2 (en) | 2012-01-13 | 2013-03-15 | EGFR modulators and uses thereof |
| US13/843,554 | 2013-03-15 | ||
| US201361814147P | 2013-04-19 | 2013-04-19 | |
| US61/814,147 | 2013-04-19 | ||
| US13/917,514 US8685988B2 (en) | 2012-08-06 | 2013-06-13 | EGFR modulators and uses thereof |
| US13/917,514 | 2013-06-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015107831A Division RU2645672C2 (ru) | 2012-08-06 | 2013-07-11 | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018104702A true RU2018104702A (ru) | 2019-02-22 |
Family
ID=50068479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018104702A RU2018104702A (ru) | 2012-08-06 | 2013-07-11 | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ |
| RU2015107831A RU2645672C2 (ru) | 2012-08-06 | 2013-07-11 | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015107831A RU2645672C2 (ru) | 2012-08-06 | 2013-07-11 | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ |
Country Status (22)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3409278B8 (en) | 2011-07-21 | 2020-11-04 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2013106792A1 (en) | 2012-01-13 | 2013-07-18 | Acea Biosciences Inc. | Heterocyclic compounds and uses as anticancer agents. |
| ES2638179T3 (es) * | 2013-01-16 | 2017-10-19 | Signal Pharmaceuticals, Llc | Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos |
| HUE044558T2 (hu) | 2013-03-14 | 2019-11-28 | Tolero Pharmaceuticals Inc | JAK és ALK2 inhibitorok és eljárások alkalmazásukra |
| CN105916851A (zh) * | 2013-07-11 | 2016-08-31 | 艾森生物科学公司 | 嘧啶衍生物作为激酶抑制剂 |
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CN106715427A (zh) | 2014-07-14 | 2017-05-24 | 西格诺药品有限公司 | 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法 |
| CN107801397B (zh) * | 2015-02-13 | 2021-07-30 | 达纳－法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
| JP2018104290A (ja) * | 2015-04-28 | 2018-07-05 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 |
| EP3312179B1 (en) | 2015-04-29 | 2019-07-10 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| AU2016334141B2 (en) * | 2015-10-09 | 2019-12-19 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| CN105646496B (zh) * | 2016-01-20 | 2018-07-20 | 华侨大学 | 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用 |
| CN107540661A (zh) * | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 |
| CN107663208B (zh) * | 2016-07-27 | 2021-10-15 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途 |
| CN107663207B (zh) * | 2016-07-27 | 2021-07-30 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法 |
| CN107955019B (zh) * | 2016-10-17 | 2021-09-14 | 广东众生药业股份有限公司 | 一种egfr抑制剂的盐型、晶型及其制备方法 |
| CN106749266B (zh) * | 2016-11-14 | 2019-01-22 | 山东大学 | 吡咯并[2,3-d]嘧啶类化合物的高效制备方法 |
| CN108299419B (zh) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
| EP3556761B1 (en) * | 2017-02-08 | 2021-03-03 | The National Institutes Of Pharmaceutical Research | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
| US11498922B2 (en) | 2017-04-07 | 2022-11-15 | ACEA Therapeutics, Inc. | Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide |
| CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
| US12180581B2 (en) | 2017-09-18 | 2024-12-31 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
| US12181452B2 (en) | 2017-09-18 | 2024-12-31 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
| US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
| US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
| IL275207B (en) | 2017-12-28 | 2022-09-01 | Daewoong Pharmaceutical Co Ltd | An oxy-fluoropiperidine derivative as a kinase inhibitor |
| KR102577241B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| WO2019195753A1 (en) | 2018-04-05 | 2019-10-10 | Tolero Pharmaceuticals, Inc. | Axl kinase inhibitors and use of the same |
| US20210113562A1 (en) | 2018-04-13 | 2021-04-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
| EP3613738A1 (en) * | 2018-08-23 | 2020-02-26 | Lead Discovery Center GmbH | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer |
| JP7662528B2 (ja) | 2019-02-12 | 2025-04-15 | スミトモ ファーマ アメリカ， インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
| CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
| CN110407840A (zh) * | 2019-08-15 | 2019-11-05 | 重庆化工职业学院 | 一种艾维替尼的制备方法 |
| EP4059935A4 (en) * | 2019-11-13 | 2024-02-28 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | PYRROLOPYRIMIDINE COMPOUND USED AS BTK INHIBITOR AND USE THEREOF |
| US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
| CN115023428B (zh) * | 2020-01-21 | 2025-04-08 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| CN111848631B (zh) * | 2020-08-28 | 2022-04-19 | 四川大学华西医院 | 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| US12352734B2 (en) | 2020-09-24 | 2025-07-08 | Waters Technologies Corporation | Chromatographic hardware improvements for separation of reactive molecules |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| JP7621624B2 (ja) * | 2021-01-11 | 2025-01-27 | 広州力▲しん▼生物科技有限公司 | ２－アミノピリミジン系化合物、その医薬組成物、及び使用 |
| CN114957248B (zh) * | 2022-05-09 | 2023-12-29 | 南开大学 | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 |
| CN115611989B (zh) * | 2022-10-09 | 2023-08-01 | 武汉理工大学 | 机械活化淀粉衍生物抑制剂的优化制备方法及应用 |
| WO2024092047A1 (en) | 2022-10-26 | 2024-05-02 | Sorrento Therapeutics, Inc. | Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis |
| WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563905A (en) | 1992-09-24 | 1996-10-08 | Hughes Aircraft Company | Network communication system having time-sliced protocol |
| DE60330022D1 (de) | 2002-07-20 | 2009-12-24 | Acea Biosciences Inc | Vorrichtungen auf impedanzbasis sowie verfahren zur verwendung in assays |
| US7470533B2 (en) | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
| US7468255B2 (en) | 2002-12-20 | 2008-12-23 | Acea Biosciences | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology |
| US7560269B2 (en) | 2002-12-20 | 2009-07-14 | Acea Biosciences, Inc. | Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays |
| US7732127B2 (en) | 2002-12-20 | 2010-06-08 | Acea Biosciences, Inc. | Dynamic monitoring of cell adhesion and spreading using the RT-CES system |
| EP1692258A4 (en) | 2003-11-12 | 2007-03-21 | Xiao Xu | REAL-TIME ELECTRONIC CELL DETECTION SYSTEMS FOR CELL-BASED TESTS |
| US8232297B2 (en) * | 2005-09-21 | 2012-07-31 | 4Sc Ag | Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| WO2011079231A1 (en) * | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
-
2013
- 2013-07-11 SM SM20170136T patent/SMT201700136T1/it unknown
- 2013-07-11 LT LTEP13745491.4T patent/LT2880035T/lt unknown
- 2013-07-11 ES ES16202341T patent/ES2733576T3/es active Active
- 2013-07-11 KR KR1020157006007A patent/KR102181365B1/ko active Active
- 2013-07-11 HU HUE13745491A patent/HUE031955T2/en unknown
- 2013-07-11 EP EP13745491.4A patent/EP2880035B9/en active Active
- 2013-07-11 EP EP16202341.0A patent/EP3170825B1/en active Active
- 2013-07-11 MX MX2015001715A patent/MX361992B/es active IP Right Grant
- 2013-07-11 SG SG11201500872SA patent/SG11201500872SA/en unknown
- 2013-07-11 RU RU2018104702A patent/RU2018104702A/ru not_active Application Discontinuation
- 2013-07-11 CN CN201710229308.7A patent/CN107266453B/zh active Active
- 2013-07-11 WO PCT/US2013/050163 patent/WO2014025486A1/en not_active Ceased
- 2013-07-11 NZ NZ629807A patent/NZ629807A/en not_active IP Right Cessation
- 2013-07-11 CA CA2881275A patent/CA2881275C/en active Active
- 2013-07-11 AU AU2013300106A patent/AU2013300106B2/en active Active
- 2013-07-11 JP JP2015526540A patent/JP6215938B2/ja active Active
- 2013-07-11 HR HRP20170311TT patent/HRP20170311T1/hr unknown
- 2013-07-11 PT PT137454914T patent/PT2880035T/pt unknown
- 2013-07-11 CN CN201380001359.4A patent/CN103748096B/zh active Active
- 2013-07-11 BR BR112015002709-1A patent/BR112015002709B1/pt active IP Right Grant
- 2013-07-11 DK DK13745491.4T patent/DK2880035T3/en active
- 2013-07-11 RU RU2015107831A patent/RU2645672C2/ru active
- 2013-07-11 IN IN914DEN2015 patent/IN2015DN00914A/en unknown
- 2013-07-11 ES ES13745491.4T patent/ES2618007T3/es active Active
-
2015
- 2015-02-02 ZA ZA2015/00762A patent/ZA201500762B/en unknown
-
2016
- 2016-01-29 ZA ZA2016/00648A patent/ZA201600648B/en unknown
-
2017
- 2017-01-17 JP JP2017005935A patent/JP2017061581A/ja not_active Withdrawn
- 2017-03-02 CY CY171100274T patent/CY1120844T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| US9840500B2 (en) | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases | |
| AU2014317119B2 (en) | Combination of a MEK inhibitor and an ERK inhibitor for use in treatment of hyperproliferative diseases | |
| RU2015108755A (ru) | Комбинация ингибитора pik3 и ингибитора с-мет | |
| RU2018110770A (ru) | Ингибиторы mdm2 и их комбинации | |
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| JP2014505735A5 (cg-RX-API-DMAC7.html) | ||
| JP2018528206A5 (cg-RX-API-DMAC7.html) | ||
| JP2015529194A5 (cg-RX-API-DMAC7.html) | ||
| JP2009536620A5 (cg-RX-API-DMAC7.html) | ||
| WO2014198942A1 (en) | Pyrazolopyridine derivatives for use in the treatment of bladder cancer | |
| JPWO2019189732A5 (cg-RX-API-DMAC7.html) | ||
| CA2473026A1 (en) | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | |
| RU2015143526A (ru) | Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака | |
| JP2016517878A5 (cg-RX-API-DMAC7.html) | ||
| RU2012148133A (ru) | Комбинация, включающая ингибитор циклинзависимой киназы 4 или циклинзависимой киназы 6 (cdk4/6) и ингибитор mtor, для лечения рака | |
| JP2014139226A5 (cg-RX-API-DMAC7.html) | ||
| JP2004527560A5 (cg-RX-API-DMAC7.html) | ||
| KR20150081344A (ko) | 조합 요법 | |
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы | |
| JP2018534314A5 (cg-RX-API-DMAC7.html) | ||
| JP2021500332A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020032105A5 (cg-RX-API-DMAC7.html) | ||
| JP2017521474A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160712 |